The company is currently raising growth capital to accelerate manufacturing and commercialization of its products and services into the life sciences market having confirmed the large opportunity and established traction with pharmaceutical and diagnostic companies.
Interested in Investing?
Contact: Juan Diaz-Mochon and David Whitcombe, co-CEOs;
emails: juan@destinagenomics.com & david@destinagenomics.com
DESTINA has developed a range of strong collaborations with Universities in the UK, Spain, Italy, Belgium and Greece, and in particular the GENYO Institute of the University of Granada (Spain). DESTINA is proud to have world-class strategic alliances and collaborations with companies, research centers and universities.
DESTINA has co-developed with Optoelettronica Italia Srl the beads-based ODG Device for nucleic acid testing. The platform comprises a novel silicon photomultiplier-based reader used in conjunction with the DGL-Tech™ and fluorescent or chemiluminescent reaction.
DESTINA is a leading and reliable partner in a number of promising European GRANTS. DESTINA’s focus is on using its innovative technology to develop novel molecular diagnostic assays across multiple high sensitivity detection platforms that are commercially available or under development.
DESTINA has recently partnered in 4 European Horizon H2020-funded consortia:
Past projects
Ongoing projects
DESTINA has been involved also in several innovative national grants in the UK and Spain. The company intends developing programs covering tests for infectious disease/pathogens in human and animal health, as well as non-invasive early tests for cancer.
Are you looking for a SME or Subcontrator as partner for your project?